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Conserved upstream open reading frames (uORFs) are
found within many eukaryotic transcripts and are known
to regulate protein translation. Evidence from genetic
and bioinformatic studies implicates disturbed uORF-
mediated translational control in the etiology of human
diseases. A genetic mouse model has recently provided
proof-of-principle support for the physiological relevance
of uORF-mediated translational control in mammals. The
targeted disruption of the uORF initiation codon within
the transcription factor CCAAT/enhancer binding protein
b (C/EBPb) gene resulted in deregulated C/EBPb protein
isoform expression, associated with defective liver
regeneration and impaired osteoclast differentiation. The
high prevalence of uORFs in the human transcriptome
suggests that intensiﬁed search for mutations within 50
RNA leader regions may reveal a multitude of alterations
affecting uORFs, causing pathogenic deregulation of
protein expression.
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Introduction
Defectivetranslationalcontrolofproteinexpressionisincreas-
ingly recognized as an important mechanism in the etiology of
human diseases [1]. In eukaryotic mRNA the main protein
coding sequence (MCS) is ﬂanked by upstream and down-
stream regulatory regions of variable length and structure.
These regions may contain multiple regulatory cis-acting
sequence elements, including 50-located hairpins, protein
binding sites, upstream open reading frames (uORFs), or
internal ribosomal entry sites (IRESs) as well as 30-located
microRNA target sites, speciﬁc localization elements (zip
codes) or polyadenylation signals. Several review articles have
summarized how such cis-regulatory translational control
elements inﬂuence translation of the MCS and how their
dysfunction relates to the development of human diseases
[2–7].
A growing body of evidence obtained from bioinformatic
and genetic studies suggests that, in particular, uORF-
mediated translational control may serve as a comprehensive
mechanism of protein expression control. Recently, the tar-
geted genetic ablation of the translational start site in the
uORF of the transcription factor CCAAT/enhancer binding
protein b (C/EBPb) validated the physiological relevance of
uORF-mediated translational control in an animal model [8].
This paper aims to provide a brief overview on uORF-
mediated translational control in general. Moreover, we show
how aberrant uORF regulation may translate into (patho)-
physiology, as illustrated by data obtained from analyses of
C/EBP transcription factors. Finally, we outline how contem-
porary sequencing technologies may help to unravel the
implications of uORF-mediated translational control in a
multitude of as-yet-unexplained human diseases.
uORFs–frequency,structure,andfunction
Translation of eukaryotic transcripts follows a coordinated
sequence of events, as summarized in the ribosomal scanning
modeloftranslation [9].Initially, a43Spre-initiationcomplex,
consisting of the 40S ribosomal subunit, the eukaryotic
initiation factor 2 (eIF2) – guanosine-50-triphosphate (GTP)
– methionyl initiator methionine-tRNA (Met-tRNAi
Met) ternary
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guanosine (m
7G) mRNA cap structure located at the 50 end
of a transcript [6]. The pre-initiation complex scans the mRNA
toward the 30 end until the Met-tRNAi
Met anticodon matches a
functional AUG codon. Joining of the 60S ribosomal subunit
completes the assembly of a fully functional ribosome and
permits initiation of translation. Initially it was assumed that
scanning ribosomes would generally initiate translation at
the m
7G-cap proximal AUG initiation codon [10], but sub-
sequently an increasing number of genes were identiﬁed that
differed from this ‘‘ﬁrst AUG rule’’. Predominantly, transcripts
with long and presumably structured 50 regulatory regions
were found to frequently contain functional AUG codons
upstream of the MCS (uAUGs) [11]. Such uAUGs constitute
the initiation codon of uORFs, and interfere with unrestrained
ribosomal scanning toward the MCS initiation codon [9].
The yeast transcription factor GCN4 represents the best-
studied example of uORF-mediated translational control and
illustrates how uORFs can facilitate the paradoxical induction
of GCN4 protein expression under conditions of reduced
global translation [12, 13]. The ﬁrst of four uORFs within the
GCN4 50 leader is efﬁciently translated under both good nutri-
tional and starvation conditions and establishes a ‘‘reinitia-
tion mode of translation’’ [14] for all downstream initiation
codons [12, 13]. In non-stressed cells, rapid reloading of post-
termination ribosomes with indispensable initiation cofactors
allows immediatereinitiation atthe proximal initiation sites of
uORFs two to four. These uORFs exhibit speciﬁc inhibitory
features, rendering the translating ribosomes incapable of
reinitiating at the MCS. During amino acid starvation the
availabilityofinitiationcofactorsdecreases,resultingindecel-
erated reloading of post-termination ribosomes and leaky
scanning across the inhibitory uORF start sites. A functional
initiation complex can only be reassembled after prolonged
progression of post-termination ribosomes, allowing the
initiation at the MCS start codon and the induction of GCN4
under stress conditions. Due to their spatial and contextual
organization, the four uORFs of the GCN4 transcript serve as a
translational switchboard that allows the cell to rapidly
respond to nutritional stress. Ultimately, the translational
induction of GCN4 and the subsequent activation of GCN4
target genes adjust the cell’s molecular repertoire to environ-
mental needs.
Mechanistically, the expression of GCN4 is determined by
thecombinedeffects ofleakyscanningandreinitiationevents,
which are sensitive to changing global translational con-
ditions. Data obtained from the GCN4 transcript showed that
the length of a uORF, the sequence context adjacent to its
termination codon and the distance to the downstream
initiation codon modulates the inhibitory effect of the uORF
on ribosomal reinitiation [12, 13]. As also conﬁrmed for other
transcripts, lengthening of the intercistronic space increases
reinitiation rates from downstream AUG codons [14], while
lengthening of the uORF itself results in decreased reinitiation
[15]. Together, these data suggest a dynamic model where
initiation cofactors are stripped from ribosomes during trans-
lation of a uORF, which need to be reassembled to allow
reinitiation to occur [9].
Bioinformatic surveys have now identiﬁed uORFs in 35–
49% of human and rodent transcripts [2, 16, 17] and correlated
the prevalence of one or multiple uORF(s) in a transcript with
reducedabundanceof therespective protein[18].Despite their
high prevalence, uORFs are less frequent than could be
expected by chance [16], and tend to be conserved among
species[19],suggestinganevolutionaryselectionoffunctional
uORFs. Recently, ribosomal proﬁling in yeast provided strong
evidencefortranslationofuORFsinvivoandconﬁrmedchang-
ing translation rates of the uORFs and the MCS of GCN4 in
response to altered nutritional conditions [20].
uORFs are extremely diverse in both structural features
and regulatory functions. As exempliﬁed for humans, uORFs
varyinlength (averageof48nt),numberpertranscript(0–13),
position (close to or distant from the mRNAs m
7G-cap, termi-
nating upstream or downstream of the MCS initiation codon),
sequence (no common uORF sequence motif has been ident-
iﬁed) and secondary structure. In approximately half of the
uORF-bearing transcripts, a single uORF precedes the MCS
initiation codon [18]. In the remaining cases, uORF-mediated
regulation is complicated by the presence of more than one
uORF, and the regulatory effect on MCS translation results
from the combined functions of individual uORFs, each acting
in a highly context-speciﬁc manner. At present, uORF-medi-
ated translational control has been validated experimentally
for about 100 eukaryotic transcripts [18]. Besides establishing
barrier functions to scanning pre-initiation ribosomes, as
exempliﬁed above for GCN4, uORFs can also reduce trans-
lation of the MCS by other means. In selected transcripts,
uORFs can provoke mRNA instability [17, 18] or render tran-
scripts susceptible to nonsense-mediated mRNA decay (NMD)
[21]. In other cases, uORF-encoded peptides repress trans-
lation of the MCS by interaction with the translational machin-
ery or by reducing mRNA stability in response to trans-acting
molecular regulators, such as sucrose [22], arginine [23] or
polyamines [24]. Mass spectrometric approaches have ident-
iﬁed a number of additional, potentially functional, uORF-
encoded peptides, which await experimental examination
[25, 26]. Despite the overt complexity of uORF-mediated trans-
lational control, several variables correlating with strong
repression of MCS translation emerge from published data.
These include long 50 cap-to-uORF distance, proximity of the
uORF to the MCS initiation site, length of the uORF, multi-
plicity of uORFs, conservation among species, and initiation
sequence context (Fig. 1) [15, 18, 27, 28].
Another intriguing regulatory function of uORFs is
observed in transcripts harboring alternative downstream
initiation sites within their MCS. In these transcripts, as exem-
pliﬁedbythetranscriptionfactorsC/EBPaandC/EBPb,uORFs
control the expression ratio of functionally distinct protein
isoforms by sensing the translational status of the cell [9, 29].
How uORF regulation translates into
(patho)physiology – the C/EBP paradigm
Evolutionarily conserved uORFs have been identiﬁed in tran-
scripts of many key regulatory genes [30, 31], implying an
important physiological role for these uORFs. Among such
uORF-bearing transcripts are the transcription factors C/EBPa
and b, which regulate the proliferation and differentiation of
multiple cell types including granulocytes, macrophages,
K. Wethmar et al. Prospects & Overviews....
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sadipocytes, osteoclasts, osteoblasts, keratinocytes, mammary
epithelial cells, and hepatocytes [32–36]. C/EBP transcription
factors are implicated in the regulation of various (patho)phy-
siological processes including metabolism, inﬂammation, and
malignant transformation [32–34, 37]. C/EBPa, b, and four
additional members (g, d, e and z) of the C/EBP family share
highly conserved C-terminal basic regions and leucine zipper
domains (bZIP), which are involved in DNA binding and
homo-orheterodimerization,respectively[34].TheN-terminal
parts of the C/EBPs are more diverse and contain regulatory
and trans-activation domains that interact with transcrip-
tional coactivators, corepressors, and the basal transcription
machinery [38–40] (Fig. 2). C/EBPb mRNA translates into two
long protein isoforms known as liver activating protein (LAP)
and LAP
 , and the truncated isoform liver inhibitory protein
(LIP). Recently, an extended C/EBPa isoform has been
described [41], in addition to the known full-length p42 and
truncated p30 isoforms. The full-length isoforms of C/EBPa
and b both contain N-terminal trans-activating and regulatory
domains that can induce differentiation and inhibit prolifer-
ation. The truncated isoforms, p30 and LIP, consist of only the
C-terminal part of C/EBPa and b, respectively, retaining their
DNAbindingcapacityandtheabilitytoformdimerswithother
protein isoforms of all C/EBP family members. The absence of
the N-terminal domains in p30 and LIP isoforms compromises
their trans-activating functions, resulting in trans-dominant
repressive effects on C/EBP target genes [42].
Inthetranscripts ofC/EBPaandb,auORFislocatedout of
frame between the initiation codons of the extended (a-ext
and LAP
 ) and the full-length isoforms (p42 and LAP) [43]
(Fig. 2). These uORFs were shown to be critical for the bal-
anced expression of the respective C/EBP isoforms [29, 44].
Unique and overlapping biological functions of the different
C/EBPa and b protein isoforms were characterized by numer-
ous cell biological studies. The short isoforms p30 and LIP are
sufﬁcient to induce lineage commitment of adipocytes [29],
hepatocytes [45], and eosinophils [46]. In addition, p30 is
sufﬁcient to commit cells to the granulocytic lineage [46],
and LIP is sufﬁcient to commit cells to the macrophage [46]
and the osteoblast [47] lineages. However, the long isoforms
are required to arrest the cell cycle of progenitors and to
induce terminal differentiation by trans-activation of cell
type-speciﬁc target genes (Fig. 3A) [29, 32, 33, 42, 45, 46,
48–53]. Due to these differential effects of C/EBP isoforms
in a variety of biological processes, uORF regulation was
suggested to be important in determining the physiological
outcome of C/EBP expression [32, 34, 37, 54].
Inmosttissues,C/EBPa-p42andC/EBPb-LAParethemost
abundant protein isoforms, despite the presence of two pre-
ceding translational initiation codons and despite a subopti-
mal initiation codon context (Fig. 4). An optimal initiation
sequence that supports initiation of virtually all scanning
ribosomes is deﬁned as CCRCCAUGG (Kozak consensus
sequence), with a purine base in position  3 and a guanine
base in position þ4 as most important for initiation [55, 56].
Figure 1. Variables affecting the degree of uORF-mediated MCS
repression. The enhancement of MCS repression correlates with
increasing m
7G to uORF distance, uORF to MCS proximity, uORF
length, number and conservation among species, and an increasingly
favorable uORF initiation context.
 These features apply to individual
transcripts but have not been validated in a bioinformatic survey
[15, 18, 27, 28]. m7G, 50 mRNA cap structure; uORF, upstream
open reading frame; MCS, main coding sequence.
Figure 2. Transcripts and protein isoforms of C/EBPa and b tran-
scription factors. Three N-terminally distinct protein isoforms (colored
bars) are translated from subsequent in-frame initiation codons
(black arrows) within the C/EBPa and b transcripts (open bars).
Small uORFs (blue) preceding the initiation codons of C/EBPa-p42
and C/EBPb-LAP regulate the balanced expression of long and
truncated protein isoforms. The C/EBPa and b isoforms contain
N-terminal trans-activating (green) and regulatory (red) domains, as
well as highly conserved C-terminal basic (orange) and leucine zipper
(purple) domains. The positions and sizes of indicated domains are
derived from published data [32, 88–91]. C/EBP, CCAAT enhancer
binding protein; ext, extended; LAP, liver activating protein; LIP, liver
inhibitory protein.
....Prospects & Overviews K. Wethmar et al.
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strong (both critical residues match the consensus sequence),
as adequate/intermediate (either residue  3o rþ4 matches)
or as weak (neither residue matches). Placing the initiation
codons of the extended isoforms of C/EBPa (intermediate)
and b (weak) in optimal Kozak consensus sequences resulted
in loss of translation from downstream initiation codons [29],
suggesting that the endogenous sequence context at the a-ext
and the LAP
  AUG codons allows leaky scanning, and does
not support complete initiation of translation. In contrast,
optimizing the Kozak context of the C/EBPa uORF start site
mildly reduced translation of p42 and enhanced the expres-
sion of p30, indicating that a fraction of the post-termination
ribosomes that had translated the uORF reinitiated at the
proximal p42 initiation codon and another fraction initiated
at the downstream p30 start site [29]. The relatively high
proportion of ribosomes that reinitiated at the p42 start site
after translating the uORF was surprising, as the C/EBPa
uORF terminates only seven bases upstream of the p42
AUG codon (Fig. 4) and intercistronic sequences of that size
were known to greatly impede reinitiation rates in other tran-
scripts[14].While strengtheningof theuORFinitiation sitesin
C/EBPa or C/EBPb resulted in an increased p30 over p42 and
LIP over LAP expression ratio, respectively, deletion of the
uORF initiation codon in eitherC/EBPaor b enhancedexpres-
sion of p42 or LAP [44] and almost completely abolished
translation of the truncated isoforms [29]. Therefore, the
‘‘intermediate’’ initiation context of p42 and LAP appeared
to be sufﬁciently strong to support initiation of most of the
scanningribosomesintheabsence,butnotinthepresence,of
uORF translation. These observations implied that translation
of the C/EBPa and b uORFs serves to shift ribosomes across
the full-length initiation sites to support truncated isoform
expression.
Several lines of evidence showed that the C/EBPa and b
uORFs integrate the signaling status of a cell to modulate the
expression ratio of isoforms. One key component in adjusting
the activity of the translational machinery to environmental
changes is the mammalian target of rapamycin kinase
(mTOR). Many nutritional and signaling pathways down-
stream of growth factor-, cytokine-, or hormone receptors alter
the activity of the mTOR kinase. Activated mTOR signaling is
associated with enhanced global translational conditions and
increased activity of important eIFs, including eIF4E [57].
Mimicking favorable translational conditions by overexpres-
sion of eIF4E induced the expression of truncated C/EBP iso-
forms p30 and LIP (Fig. 3B) and was associated with increased
initiation at the uORF start site [29]. Importantly, mutation of
the uORF initiation codon abolished the eIF4E-mediated
induction of short C/EBP isoforms, conﬁrming that indeed
translation of the uORF was required to shift initiation toward
the distal initiation codons [29]. In turn, inhibition of mTOR
kinase activity by the macrolide antibiotic rapamycin, protein
folding stress or nutrient depletion decreased global transla-
tional activity and was associated with the predominant pro-
duction of p42 and LAP isoforms [29] (Fig. 3B). In response to
rapamycin treatment, a shift of expression toward the full-
length C/EBPbprotein isoformwasalsoobservedforendogen-
ous transcripts and was shown to affect cellular fates, e.g. the
differentiation of osteoclasts [35] or the proliferation of malig-
nant cells [58]. Increased LIP over LAP isoform ratios were
observed in several malignancies including Hodgkin lym-
phoma, anaplastic large cell lymphoma [58], and aggressive
forms of breast cancer (reviewed in Ref. 37). Moreover, trans-
genic expression of LIP in mammary glands resulted in hyper-
plasia and tumorigenesis in mice, suggesting a pro-
proliferative and tumorigenic potential of the LIP isoform
Figure 3. C/EBPa and b isoform expression ratios affect cellular
proliferation and differentiation, and are modulated in response to
mTOR signaling. A: Several examples of how the C/EBP isoform
ratio affects cellular differentiation are illustrated, speciﬁcally how an
increase in the short isoforms p30 and LIP disrupts proper differen-
tiation. For example, p30 and LIP are overexpressed in several
human cancers, including AML and breast cancer, respectively. The
truncated isoforms are sufﬁcient to induce lineage commitment of
proliferative progenitor cells; however, they are not capable of block-
ing the cell cycle (indicated with the circular arrow) and inducing ter-
minal differentiation and maturation.
  In these cases, similar isoform
speciﬁc functions have been described for both, C/EBPa and b.
B: Environmental signals enhance (green) or repress (red) mTOR
kinase activity, resulting in changes in global translational conditions.
Changes in the translational status have been shown to affect uORF
translation, resulting in changes in C/EBP protein isoform balance. In
a good translational status, the C/EBPa and b uORFs may be more
frequently translated, shifting the isoform expression ratio toward the
truncated C/EBPa (p30) and b (LIP) isoforms (green).
K. Wethmar et al. Prospects & Overviews....
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bition of mTOR altered the isoform ratio in favor of LAP and
resulted in a decrease in tumor cell proliferation [58, 60, 61].
Together, these data suggested that the uORF initiation
codon may serve as a physiologically important sensor of global
translational conditions, shifting the isoform expression ratio
towardthetruncatedisoformsunderfavorableconditionsandto
the full-length isoforms under unfavorable conditions. This
function may be due to the suboptimal Kozak context that
surrounds the uORF initiation codon (Fig. 4), which allows
themodulationofinitiationratesinresponsetothetranslational
status. Interestingly, although surrounded by an intermediate
Kozakcontextaswell,initiationratesatthefull-lengthinitiation
codon appear to be not as sensitive to changing translational
conditions. Lower variability of full-length initiation may be
attributed to its location downstream of the uORF and to the
fact that it is efﬁciently used already under steady-state con-
ditions, but the molecular mechanisms driving the preferential
use of the uORF initiation codon under favorable translational
conditions remain to be identiﬁed. Despite the simplicity of a
linear ribosomal scanning/reinitiation model as an explanation
for uORF-mediated control of isoform expression, the
translational regulation of C/EBP transcription factors might
be more complex. Three-dimensional stem loop structures
[62], regulatory trans-acting factors including CUGBP1 [63] as
well as hnRNP-microRNA interactions [64] were shown to affect
C/EBP translation. Nevertheless, translation of the uORF is
required to drive expression of the truncated C/EBP isoforms
and represents a major determinant in the regulation of isoform
expression ratios.
The recent generation of genetically altered mice, carrying
asinglenucleotideexchangeoftheATGuORFinitiationcodon
to TTG in the C/EBPb gene (C/EBPb
DuORF), now conﬁrmed the
concept of uORF-mediated isoform expression in vivo and
contributed to a deeper understanding of how changes in
the isoform ratio of C/EBPb affect mammalian physiology
[8]. The C/EBPb
DuORF mice were generated using homologous
recombination into the endogenous c/ebpb gene locus. The
DuORF mutation eliminates the uORF initiation codon and
thus disrupts its function as molecular switch to induce the
truncated LIP isoform, without alteration of the amino acid
sequence of C/EBPb. Data obtained from the C/EBPb
DuORF
homozygousmiceshowedthattheC/EBPbisoformproduction
becomes unresponsive to extracellular stimuli, such as lip-
opolysaccharide treatment, which normally increases the LIP
to LAP ratio [8]. Furthermore, ablation of uORF initiation
prevented the physiological induction of LIP during liver
regeneration. Lack of LIP expression resulted in enhanced
acute phase response,prolonged repression of cell cyclegenes
and impaired cell cycle entry of hepatocytes after partial
hepatectomy [8]. In a second recombinant mouse model
(C/EBPb
LIP), the endogenous c/ebpb gene locus was replaced
by the coding sequence of the LIP isoform only, resulting in
complete loss of expression of LAP
  and LAP. The exclusive
expressionofLIPintheseanimalsrescuedboththeexpression
of cell cycle genes and the entry of hepatocytes into S phase
[8]. Furthermore, C/EBPb
LIP mice displayed enhanced differ-
entiation of bone-resorbing osteoclasts, while in turn, the
decreased LIP to LAP isoform ratio in C/EBPb
DuORF mice
showed an impaired osteoclast differentiation. The C/EBPb
LAP isoform was found to induce the expression of the
Figure 4. Validated and hypothetical uORFs in C/EBP transcription
factors. C/EBPa and b transcripts of human (homo), cow (bos), and
mouse (mus) contain experimentally validated uORFs (gray back-
ground color) terminating 7 and 4 nucleotides in front of the p42 and
LAP initiation codon, respectively. The most abundant C/EBPe tran-
script variant [79] contains three subsequent hypothetical uORF
initiation codons (uORF
hyp), followed by in-frame termination codons
upstream (homo) or downstream (bos and mus) of the p30 start site.
The rat C/EBPe sequence is not displayed, as it is 100% homolo-
gous to the mouse sequence shown in this alignment. Initiation
codons of protein isoforms are highlighted by green background
color, initiation and termination codons of uORFs and uORFs
hyp are
in red bold face, favorable residues of the core Kozak context (resi-
dues at  3o rþ4) are underlined.
  This uORF
hyp initiation codon
may be nonfunctional, as its presence did not prevent deregulated
C/EBPb isoform expression when the uORF AUG codon ( 34) was
mutated to a non-functional UUG codon [8, 29].
....Prospects & Overviews K. Wethmar et al.
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sequesters other transcription factors that are known to medi-
ate osteoclastic differentiation, including Fos, Nfatc1, and
Mitf. In contrast, LIP downregulates MafB expression, result-
ing in increased availability of those osteoclastic transcription
factors [8, 35, 65]. In summary, the C/EBPb
DuORF mouse com-
prises the ﬁrst genetic animal model that conﬁrms the phys-
iological signiﬁcance of uORF translation in vivo and its action
asamolecularswitchdrivingcellfatedecisionsbymodulating
isoform expression ratios. The in vivo data support the idea
that the abundance of individual C/EBPb isoforms isregulated
by uORF-mediated integration of cellular signals, resulting in
tissue-speciﬁc functions that depend on the cellular context.
These and other data also challenge the model of LIP being
a general transcriptional repressor and of LAP
 /LAP acting as
general trans-activators. LIP hasnow beendescribed asatrans-
activatorinseveralsituations,e.g.ontargetgenescontainingC/
EBP-responsive promoter elements that can be mutually acti-
vated by LIP or cyclin D1 [66], as well as in osteoblasts by
interactionwiththeosteoblastictranscriptionfactorRunx2[47].
The trans-activation potential of LIP might be explained by LIP
out-competing the repressive effects of long C/EBP
isoforms, as described for E2F target genes [8, 67, 68].
Moreover, LIP may enhance differentiation of osteoblasts and
osteoclasts [35]. These observations suggest a high versatility
and target gene speciﬁcity in C/EBPb isoform functions.
For C/EBPa, data obtained from patients and targeted
mouse genetics also argue for critical physiological functions
of the C/EBPa uORF in balanced isoform expression. C/EBPa
is an inducer of terminal differentiation in granulocytes and
couples induction of cell type-speciﬁc genes to cell cycle arrest
[32, 33, 69]. The C/EBPa full-length isoform p42, similar to the
long isoforms of C/EBPb, blocks cell cycle progression by
repressing E2F target genes, a function that is required in
terminal cellular differentiation. In contrast, the truncated
p30 isoform is not capable of repressing E2F target genes,
and therefore proliferation continues, preventing terminal
differentiation [70–72]. C/EBPa is mutated in about 10% of
patients with acute myeloid leukemia (AML), where the most
common mutations result in the loss of p42 expression, while
the production of p30 is preserved [73–76]. A myeloid prolif-
erative phenotype due to loss of p42 expression was also
observed in knock-in mice that express p30 only [77]. These
mice displayed disturbed granulopoiesis and premature
death. Presence of p30 was sufﬁcient for progenitor commit-
ment to the granulocyte-macrophage cell lineage; however,
p42 was required to restrain proliferation of these myeloid
progenitors,anditsabsenceresultedinamyeloidproliferative
disease resembling human AML [77]. Furthermore, pharma-
cologically induced differentiation of AML cells by the triter-
penoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO)
required an intact uORF [78]. Underlining the critical import-
ance of the C/EBPa uORF, a null mutation of its initiation
codon in mice results in early embryonic lethality (A. Bremer
and C. F. Calkhoven, personal communication).
Another example of how isoform expression ratios affect
cell fate decisions comes from C/EBPe, the third C/EBP family
member that is produced as various N-terminally truncated
isoforms. The C/EBPe gene differs structurally from C/EBPa
and b in that it contains introns. In addition to alternative
translational initiation, the expression of four alternative
C/EBPe isoforms (p32, p30, p27, and p14) was attributed to
differential promoter usage and alternative splicing. Similar to
the short C/EBPa and b isoforms, the short C/EBPe isoforms
display less trans-activation potential, with the shortest iso-
form (p14) virtually lacking trans-activating domains
[79–81]. C/EBPe is expressed in hematopoietic cells of the
granulocytic lineage, and is required for the terminal differ-
entiation of granulocytes into eosinophils and neutrophils
[79, 80, 82]. Recent studies showed that the isoforms of
C/EBPe differentially affect granulocytic lineage commitment
and differentiation pathways [81]. Despite many structural
and functional similarities between C/EBPa, b, and e,i t
remains to be determined whether uORF-mediated transla-
tional control also affects C/EBPe isoform expression. Only the
murine and rat transcripts contain an out-of-frame uAUG
codon between the p32 and the p30 translational start site
(Fig. 4). Nevertheless, as many as three conserved hypothet-
ical C/EBPe uORFs could initiate from alternative out-of-frame
initiation codons in the human transcript, such as ACG at  89
and  77 (which corresponds to the mouse and rat uAUG) or
GUG at  59 in respect to the adenine base in the p30 initiation
codon (Fig. 4). All three hypothetical uORF (uORF
hyp) start
sites are conserved, but the uORF
hyp terminates ﬁve bases
upstream of the p30 initiation codon only in humans, while
in cow and mouse it overlaps the p30-coding sequence by 85
nucleotides. Given that all three potential uORF start sites are
surrounded by intermediate or favorable Kozak consensus
sequences, uORF-mediated translational control might be
an additional level of C/EBPe expression regulation.
Mutant uORFs accounting for human
diseases
In analogy to the experimentally deleted C/EBPb uORF
initiation codon in C/EBPb
DuORF mice, naturally occurring
uORF mutations in other genes may cause physiological alter-
ations by deregulating translation of the affected transcript.
Suchmutations couldeitherchange thepresenceof auORF by
generating or deleting an initiation codon upstream of the
MCS start site, or could affect translational control by chang-
ing one of the structural features of an existing uORF (Fig. 1).
More than 500 single nucleotide polymorphisms (SNPs) have
been identiﬁed in humans that either create or delete uORFs,
highlighting the potential physiological implications of uORF-
mediated translational control. This variability in the presence
of uORFs may suggest a substantial contribution of uORF-
mediated regulation to individual phenotypes and/or the pre-
disposition to distinct diseases [18]. To date, three well-docu-
mented and thoroughly analyzed uORF-affecting mutations
have been linked to the development of human diseases:
(i) hereditary thrombocythemia is caused by a mutation that
eliminates a uORF due to the generation of an alternatively
spliced mRNA, resulting in increased production of thrombo-
poietin protein [83]; (ii) reduced production of cyclin-depend-
entkinaseinhibitor2A,causedbyamutationthatintroducesa
uORF in the 50 leader sequence of the CDKN2A transcript,
results in familial predisposition to melanoma development
[84]; and (iii) Marie Unna hereditary hair loss is caused by
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log (HR) transcript, causing an increased expression of the
hairless homolog protein [85]. This list was recently extended
by 11 disease-related genes, where uORF-altering mutations
were identiﬁed by computational analysis of the Human
Gene Mutation Database [18]. Diseases with conﬁrmed
uORF mutations include the van der Woude syndrome
(IRF6), hereditary pancreatitis (SPINK1), and familial hyper-
cholesterolemia (LDLR) [18]. Additionally, the expression of
the beta secretase BACE1, related to Alzheimer’s disease [86],
or the transmembrane receptor tyrosin kinase ERBB2, related
to breast cancer [87], is at least partially controlled by uORFs.
Whether deregulated uORF-mediated translational control is
the crucial pathogenic event inthese latter cases remains to be
established. Even with only a few unequivocal cases at this
time, it is evident that uORF mutations may be involved in a
wide variety of diseases including malignancies, metabolic or
neurologic disorders, and inherited syndromes. As many
important regulatory proteins, including cell surface recep-
tors, tyrosine kinases, and transcription factors act in a dose-
dependent fashion, uORF mutations that affect expression
levels of these genes might be responsible for a number of
as-yet-unexplained pathologies.
Conclusions and prospects
The recent validation of the (patho)physiological importance
of uORF translation in mice added a new level of signiﬁcance
to this cis-regulatory mechanism of translational control.
C/EBPa and b transcription factors represent well-estab-
lished examples of how translational control by uORFs
may affect cell fate decisions. Accumulating evidence
suggests that deregulated uORF function might be a wide-
spread mechanism underlying the development of human
diseases. The rapid progress in advanced sequencing tech-
nologies will permit screening approaches to identify caus-
ative uORF mutations in primary material derived from
patients. Malignancies of the blood might be among the most
suitable types of diseases to start such an analysis, as cell
samples are readily accessible. One would, e.g.e x p e c tt o
uncover mutations resulting in a ‘‘loss of uORF function’’
in proto-oncogenes, causing their ectopic and transform-
ation-inducing overexpression. In turn, mutations yielding
a ‘‘gain of uORF function’’ in tumor suppressor genes may
result in malignant transformation due to a decreased pro-
duction of protective proteins (Fig. 5). Given the high number
ofhumantranscripts carryingatleastoneuORF,thein-depth
analysis of 50 leader sequence mutations has the potential to
substantially widen the spectrum of diseases with molecu-
larly resolved etiology. Uncovering disease-related uORF
mutations will inspire extensive subsequent research aiming
to target the misexpressed proteins for therapeutic
intervention.
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